(LQDA) Liquidia Technologies - Ratings and Ratios
Inhaled,Liquid,Artery,Cancer,Pulmonary
LQDA EPS (Earnings per Share)
LQDA Revenue
Description: LQDA Liquidia Technologies August 13, 2025
Liquidia Technologies Inc (NASDAQ:LQDA) is a US-based pharmaceutical company. The companys stock has demonstrated significant price support levels, with key thresholds at $19.4, $16.3, $15.4, and $14.1, indicating potential areas of buying interest.
From a fundamental analysis perspective, Liquidia Technologies has a market capitalization of approximately $1.74 billion. The absence of a price-to-earnings (P/E) ratio, either trailing or forward, suggests that the company is currently unprofitable. The return on equity (ROE) stands at -170.31%, highlighting substantial losses relative to shareholder equity. This metric indicates that the company is not generating profits from shareholder equity, potentially due to significant R&D expenses or operational costs.
Key economic drivers for Liquidia Technologies include the development and commercialization of its pharmaceutical products, as well as the competitive landscape within the pharmaceutical industry. The companys ability to secure regulatory approvals, manage clinical trials, and bring products to market will be crucial in driving future revenue growth. Other relevant KPIs may include revenue growth rate, R&D expense as a percentage of revenue, and cash burn rate.
To evaluate the stocks potential, its essential to monitor the companys progress in advancing its product pipeline, achieving regulatory milestones, and managing its financial resources. A thorough analysis of the companys cash position, funding requirements, and potential for future profitability will be necessary to assess the stocks long-term viability.
LQDA Stock Overview
| Market Cap in USD | 1,933m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2018-07-26 |
LQDA Stock Ratings
| Growth Rating | 93.3% |
| Fundamental | 28.2% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 84.9% |
| Analyst Rating | 4.30 of 5 |
LQDA Dividends
Currently no dividends paidLQDA Growth Ratios
| Growth Correlation 3m | -32.5% |
| Growth Correlation 12m | 82.3% |
| Growth Correlation 5y | 93.3% |
| CAGR 5y | 70.14% |
| CAGR/Max DD 3y (Calmar Ratio) | 1.50 |
| CAGR/Mean DD 3y (Pain Ratio) | 3.84 |
| Sharpe Ratio 12m | 0.95 |
| Alpha | 114.18 |
| Beta | 0.157 |
| Volatility | 59.28% |
| Current Volume | 3088.5k |
| Average Volume 20d | 1994.2k |
| Stop Loss | 22.7 (-6.8%) |
| Signal | 1.35 |
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income (-141.5m TTM) > 0 and > 6% of Revenue (6% = 1.16m TTM) |
| FCFTA -0.48 (>2.0%) and ΔFCFTA 1.26pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 606.4% (prev 829.1%; Δ -222.7pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.45 (>3.0%) and CFO -116.1m > Net Income -141.5m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 2.49 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (85.6m) change vs 12m ago 11.97% (target <= -2.0% for YES) |
| Gross Margin 70.36% (prev 65.70%; Δ 4.65pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 8.89% (prev 8.37%; Δ 0.52pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -7.10 (EBITDA TTM -123.8m / Interest Expense TTM 17.7m) >= 6 (WARN >= 3) |
Altman Z'' -11.73
| (A) 0.46 = (Total Current Assets 195.6m - Total Current Liabilities 78.4m) / Total Assets 257.4m |
| (B) -2.48 = Retained Earnings (Balance) -637.3m / Total Assets 257.4m |
| warn (B) unusual magnitude: -2.48 — check mapping/units |
| (C) -0.58 = EBIT TTM -125.6m / Avg Total Assets 217.4m |
| (D) -2.63 = Book Value of Equity -637.2m / Total Liabilities 242.2m |
| Total Rating: -11.73 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 28.19
| 1. Piotroski 1.50pt = -3.50 |
| 2. FCF Yield -6.85% = -3.42 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 3.35 = -1.28 |
| 5. Debt/Ebitda 0.99 = 1.78 |
| 6. ROIC - WACC (= -63.16)% = -12.50 |
| 7. RoE -223.9% = -2.50 |
| 8. Rev. Trend 10.37% = 0.78 |
| 9. EPS Trend -23.36% = -1.17 |
What is the price of LQDA shares?
Over the past week, the price has changed by +8.85%, over one month by +7.12%, over three months by +30.34% and over the past year by +124.52%.
Is Liquidia Technologies a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of LQDA is around 35.64 USD . This means that LQDA is currently undervalued and has a potential upside of +46.31% (Margin of Safety).
Is LQDA a buy, sell or hold?
- Strong Buy: 6
- Buy: 3
- Hold: 0
- Sell: 0
- Strong Sell: 1
What are the forecasts/targets for the LQDA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 36.9 | 51.4% |
| Analysts Target Price | 36.9 | 51.4% |
| ValueRay Target Price | 39.1 | 60.4% |
LQDA Fundamental Data Overview October 31, 2025
P/S = 100.0286
P/B = 124.1377
Beta = 0.157
Revenue TTM = 19.3m USD
EBIT TTM = -125.6m USD
EBITDA TTM = -123.8m USD
Long Term Debt = 149.5m USD (from longTermDebt, last quarter)
Short Term Debt = 44.5m USD (from shortTermDebt, last quarter)
Debt = 50.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -122.5m USD (from netDebt column, last quarter)
Enterprise Value = 1.81b USD (1.93b + Debt 50.9m - CCE 173.4m)
Interest Coverage Ratio = -7.10 (Ebit TTM -125.6m / Interest Expense TTM 17.7m)
FCF Yield = -6.85% (FCF TTM -124.0m / Enterprise Value 1.81b)
FCF Margin = -641.6% (FCF TTM -124.0m / Revenue TTM 19.3m)
Net Margin = -732.2% (Net Income TTM -141.5m / Revenue TTM 19.3m)
Gross Margin = 70.36% ((Revenue TTM 19.3m - Cost of Revenue TTM 5.73m) / Revenue TTM)
Gross Margin QoQ = 85.38% (prev 51.38%)
Tobins Q-Ratio = 7.03 (Enterprise Value 1.81b / Total Assets 257.4m)
Interest Expense / Debt = 11.11% (Interest Expense 5.66m / Debt 50.9m)
Taxrate = 21.0% (US default 21%)
NOPAT = -99.3m (EBIT -125.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.49 (Total Current Assets 195.6m / Total Current Liabilities 78.4m)
Debt / Equity = 3.35 (Debt 50.9m / totalStockholderEquity, last quarter 15.2m)
Debt / EBITDA = 0.99 (negative EBITDA) (Net Debt -122.5m / EBITDA -123.8m)
Debt / FCF = 0.99 (negative FCF - burning cash) (Net Debt -122.5m / FCF TTM -124.0m)
Total Stockholder Equity = 63.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -54.96% (Net Income -141.5m / Total Assets 257.4m)
RoE = -223.9% (Net Income TTM -141.5m / Total Stockholder Equity 63.2m)
RoCE = -59.09% (EBIT -125.6m / Capital Employed (Equity 63.2m + L.T.Debt 149.5m))
RoIC = -56.52% (negative operating profit) (NOPAT -99.3m / Invested Capital 175.6m)
WACC = 6.65% (E(1.93b)/V(1.98b) * Re(6.59%) + D(50.9m)/V(1.98b) * Rd(11.11%) * (1-Tc(0.21)))
Discount Rate = 6.59% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 14.38%
Fair Price DCF = unknown (Cash Flow -124.0m)
EPS Correlation: -23.36 | EPS CAGR: 6.35% | SUE: 4.0 | # QB: 1
Revenue Correlation: 10.37 | Revenue CAGR: 45.26% | SUE: 2.45 | # QB: 1
Additional Sources for LQDA Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle